Preclinical Results of BizenCell Atopy Treatment 'VM-AD' Selected as Presentation Topic at American Immunology Society Meeting

[Asia Economy Reporter Lee Gwan-joo] VigenCell, a company specializing in immune cell therapy development, announced on the 2nd that the preclinical results of ‘VM-AD,’ an atopic dermatitis treatment candidate, have been selected as an official presentation topic at the American Association of Immunologists conference to be held in May.

The ‘Immunology 2022™’ conference of the American Association of Immunologists, where VigenCell will present its preclinical results, is a global academic conference where immunology experts from around the world share the latest research findings and build networks. This event will be held from May 6 to 10 in Portland, Oregon, USA.

At this event, VigenCell will present the preclinical results of ‘VM-AD,’ an atopic dermatitis treatment based on ViMedier™, a cord blood stem cell-derived myeloid-derived suppressor cell therapy platform technology, through both oral and poster presentations.

Tae-kyu Kim, CEO of VigenCell, said, “More than 100 million atopic dermatitis patients worldwide suffer from symptoms such as itching, which lowers their quality of life. Through this presentation, we aim to showcase the strengths of VM-AD to the global market and sequentially proceed with clinical trials to become a new alternative for atopic dermatitis treatment.”

VigenCell’s ViMedier is based on the world’s first large-scale culture technology for myeloid-derived suppressor cells, enabling expansion into various indications. In addition to the atopic dermatitis treatment ‘VM-AD,’ VigenCell also has ‘VM-GD,’ targeting graft-versus-host disease (GvHD), in its pipeline.

This content was produced with the assistance of AI translation services.